Open AccessCost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
Author(s) -
Vladislav Berdunov,
Steve Millen,
Andrew Paramore,
Jane Griffin,
Sarah Reynia,
Nina Fryer,
Rebecca Brown,
Louise Longworth
Publication year - 2022
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s360049
Subject(s) - medicine , breast cancer , oncology , gynecology , test (biology) , obstetrics , cancer , biology , paleontology
The 21-gene assay (the Oncotype DX Breast Recurrence Score ® test) is a validated multigene assay which produces the Recurrence Score ® result (RS) to inform decisions on the use of adjuvant chemotherapy in human epidermal growth factor receptor 2-negative (HER2-), hormone receptor positive (HR+) early invasive breast cancer. A model-based economic evaluation estimated the cost-effectiveness of the 21-gene assay against the use of clinical risk tools alone based on the latest evidence from prospective studies.